Alzheimer disease (AD), cerebrovascular diseases, Lewy body disease, and limbic-predominant age-associated transactive response DNA-binding protein 43 (TDP-43) encephalopathy are primary causes of dementia.
1,2 However, these neuropathologic conditions are also commonly observed among elderly individuals who died without dementia or cognitive impairment.
3 Data from clinical-pathologic studies show that only a portion of person-specific cognitive decline may be explained by common neuropathologic indices,
4 suggesting that many other factors play a role. Although some factors, such as neurodegeneration, are downstream events of neuropathologic conditions, other factors are associated with cognitive decline without working through neuropathologic conditions. Of particular interest is that brains differ in their ability to tolerate various proteinopathies, vessel diseases, and vascular tissue injuries, and this ability is associated with cognitive resilience. Identifying genes and proteins for cognitive resilience (ie, targets that are associated with slowing or preventing cognitive decline regardless of the presence, number, or combination of common neuropathologic conditions) provides a complementary approach to developing new therapeutics for the treatment and prevention of AD and related dementias. Prior research has shown that neural reserve and synaptic proteins may act to maintain late-life cognition, above and beyond the association of neuropathologic conditions with cognition,
5-7 while other genes may be associated with a reduction in the deleterious effect of AD pathologic conditions.
8 Most of these studies target specific genes and proteins a priori, and it is possible that additional proteins associated with cognitive resilience await discovery.